SRX Global Announces Activation of the University of California, Davis as a Clinical Trial Site for CERo Therapeutics' Ongoing Phase 1 CERTAIN-T Trial of CER-1236 in Hematologic Malignancies

UC Davis is the primary manufacturing site for CER-1236. Site activation is expected to expand patient recruitment capacity and streamline treatment logistics; the article provides no figures on the scale or timing of the expected gains.